Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): Speed is life

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 5, 2011, Pages 959-963

  Kumar, Anand ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Department of Anesthesiology   (United States)

Author keywords

Antivirals; Critical care; Outcome; Therapy; Virus

Indexed keywords

OSELTAMIVIR; SIALIDASE INHIBITOR;

2009 H1N1 INFLUENZA; ANTIVIRAL THERAPY; ARTICLE; COMPLICATION; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; FEVER; HUMAN; INFLUENZA A; INFLUENZA B; OBSERVATIONAL STUDY; SURVIVAL; THERAPY DELAY; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; CRITICAL ILLNESS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; OSELTAMIVIR; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79954624543     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr090     Document Type: Article

References (49)

1. Talan DA, Guterman JJ, Overturf GD et al. Analysis of emergency department management of suspected bacterial meningitis. Ann Emerg Med 1989; 18: 845-62.
2. Funk DJ, Kumar A. Antimicrobial therapy for life-threatening infections: speed is life. Crit Care Clin 2011; 27: 53-76.
3. Lebel MH, McCracken J. Delayed cerebrospinal fluid sterilization and adverse outcome of bacterial meningitis in infants and children. Pediatrics 1989; 83: 161-7.
4. Lebel MH. Adverse outcome of bacterial meningitis due to delayed sterilization of cerebrospinal fluid. Antibiot Chemother 1992; 45: 226-38.
5. Meehan TP, Fine MJ, Krumholz HM et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997; 278: 2080-4.
6. Lodise TP, Patel N, Kwa A et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: Impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 2007; 51: 3510-5.
7. Kang CI, Kim SH, Kim HB et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003; 37: 745-51.
8. Mathevon T, Souweine B, Traore O et al. ICU-acquired nosocomial infection: impact of delay of adequate antibiotic treatment. Scand J Infect Dis 2002; 34: 831-5.
9. Iregui M, Ward S, Sherman G et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122: 262-8.
10. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
11. Patel GP, Simon D, Scheetz M et al. The effect of time to antifungal therapy on mortality in candidemia associated septic shock. Am J Ther 2009; 16: 508-11.
12. Kumar A, Haery C, Paladugu B et al. The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: association with serum lactate and inflammatory cytokine levels. J Infect Dis 2006; 193: 251-8.
13. Kumar A, Roberts D, Wood KE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-96.
14. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-a therapy. Science 1998; 282: 103-7.
15. Jaeckel E, Cornberg M, Wedemeyer H et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345: 1452-7.
16. Lam NP, Neumann AU, Gretch DR et al. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26: 226-1.
17. Domingues RB, Lakeman FD, Mayo MS et al. Application of competitive PCR to cerebrospinal fluid samples from patients with Herpes simplex encephalitis. J Clin Microbiol 1998; 36: 2229-34.
18. Dutkowski R, Thakrar B, Froehlich E et al. Safety and pharmacology of oseltamivir in clinical use. Drug Saf 2003; 26: 787-801.
19. Hayden FG, Jennings L, Robson R et al. Oral oseltamivir in human experimental influenza B infection. Antivir Ther 2000; 5: 205-13.
20. Treanor JJ, Hayden FG, Vrooman PS et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000; 283: 1016-24.
21. Nicholson KG, Aoki FY, Osterhaus ADME et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 2000; 355: 1845-50.
22. Falagas ME, Koletsi PK, Vouloumanou EK et al. Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010; 65: 1330-46.
23. McGeer A, Green KA, Plevneshi A et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45: 1568-75.
24. Lee N, Cockram CS, Chan PKS et al. Antiviral treatment for patients hospitalized with severe influenza infection may affect clinical outcomes. Clin Infect Dis 2008; 46: 1323-4.
25. Lee N, Chan PKS, Kin WC et al. Factors associated with early hospital discharge of adult influenza patients. Antivir Ther 2007; 12: 501-8.
26. Lee N, Choi KW, Chan PKS et al. Outcomes of adults hospitalised with severe influenza. Thorax 2010; 65: 510-5.
27. Hanshaoworakul W, Simmerman JM, Narueponjirakul U et al. Severe human influenza infections in Thailand: oseltamivir treatment and risk factors for fatal outcome. PLoS ONE 2009; 4: e6051.
28. Hassan K, McGeer A, Green KA et al. Antiviral therapy improves outcome of influenza infections in patients requiring admission to intensive care. In: Abstracts of the Forty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract V537. American Society for Microbiology, Washington, DC, USA.
29. Admisamito W, Chan PKS, Lee N et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a global patient registry. J Infect Dis 2010; 202: 1154-60.
30. Dominguez-Cherit G, Lapinsky SE, Espinosa-Perez L et al. Critically ill patients with influenza A (novel H1N1) in Mexico. JAMA 2009; 302: 1880-7.
31. Aoki FY, Macleod MD, Paggiaro P et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003; 51: 123-9.
32. To KKW, Hung IFN, Li IWS et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis 2010; 50: 850-9.
33. Lee N, Chan PKS, Hui DSC et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 200: 492-500.
34. Ling LM, Chow AL, Lye DC et al. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. Clin Infect Dis 2010; 50: 963-9.
35. Li IW, Hung IF, To KK et al. The natural viral load profile of patients with pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment. Chest 2010; 137: 759-68.
36. Singh S, Barghoorn J, Bagdonas A et al. Clinical benefits with oseltamivir in treating influenza in adult populations: results of a pooled and subgroup analysis. Clin Drug Invest 2003; 23: 561-9.
37. Orzeck EA, Shi N, Blumentals WA. Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes. Clin Ther 2007; 29: 2246-55.
38. Kaiser L, Wat C, Mills T et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163: 1667-72.
39. Jain S, Kamimoto L, Bramley AM et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361: 1935-44.
40. Louie JK, Acosta M, Jamieson DJ et al. Severe 2009 H1N1 influenza in pregnantand postpartumwomenin California. N Engl J Med 2010; 362: 27-35.
41. Siston AM, Rasmussen SA, Honein MA et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA 2010; 303: 1517-25.
42. Zarychanski R, Stuart TL, Doucette S et al. Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection. CMAJ 2010; 182: 257-64.
43. Rodríguez A, Díaz E, Martín-Loeches I et al. Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. J Antimicrob Chemother 2011; 66: 1140-9.
44. Hiba V, Chowers M, Levi-Vinograd I et al. Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): retrospective cohort study. J Antimicrob Chemother 2011; 66: 1150-5.
45. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 2007; 16: 241-9.
46. Shintani AK, Girard TD, Eden SK et al. Immortal time bias in critical care research: application of time-varying Cox regression for observational cohort studies. Crit Care Med 2009; 37: 2939-45.
47. Zarychanski R, Doucette S, Fergusson D et al. Early intravenous unfractionated heparin and mortality in septic shock. Crit Care Med 2008; 36: 2973-9.
48. Bautista E, Chotpitayasunondh T, Gao Z et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362: 1708-19.
49. WHO Guidelines for Pharmacologic Management of Pandemic (H1N1) 2009 Influenza and Other Influenza Viruses. Geneva: WHO, 2009.